Table 3.
In-vitro drug assay results
| Carboplatin | Cisplatin | Paclitaxel* | Docetaxel | |
|---|---|---|---|---|
| EDR | 7.9 | 6.9 | 23.2 | 13.6 |
| IDR | 25.7 | 20.7 | 31.4 | 36.7 |
| LDR | 66.4 | 72.3 | 45.3 | 49.7 |
| Cyclophos | Doxil | Doxorubicin | Etoposide | |
|---|---|---|---|---|
| EDR | 18.5 | 32.4 | 44.6 | 31.9 |
| IDR | 30.3 | 36.4 | 24.6 | 38 |
| LDR | 51.3 | 31.3 | 30.8 | 30.1 |
| Fluorouracil | Gemcitabine | Ifosamide | Topotecan | |
|---|---|---|---|---|
| EDR | 25.3 | 7.9 | 22.4 | 17.2 |
| IDR | 28 | 10.9 | 20.9 | 32.5 |
| LDR | 46.7 | 81.2 | 56.7 | 50.2 |
Percentage is shown.
*
p<0.05 (Paclitaxel EDR vs platinum and docetaxel EDR).
Abbreviations: cyclophos, cyclophosphamide; EDR, extreme drug resistance; IDR, intermittent drug resistance; and LDR, low drug resistance.